The new assay, described in Plant Cell Reports, relies on LwaCas13a, a type VI CRISPR effector protein originally harnessed for human pathogen detection in the SHERLOCK platform. Unlike Cas9 or Cas12, Cas13 targets RNA rather than DNA and does not require a protospacer adjacent motif, which simplifies guide design considerably. Once the protein’s CRISPR RNA guide finds a complementary viral sequence, the enzyme undergoes a conformational change that unleashes indiscriminate collateral cleavage of nearby single-stranded RNA. The researchers exploit this behavior with a fluorescent reporter oligonucleotide carrying a FAM fluorophore on one end and a quencher on the other; cleavage separates the two molecules, producing a measurable rise in fluorescence that signals a positive detection.

To build the test, the team obtained sequence data for all three viruses from the USDA-APHIS Plant Germplasm Quarantine Program in Maryland and aligned the genomes using the MUSCLE algorithm in Geneious Prime software. They designed five candidate 28-nucleotide crRNA target sites for each virus and screened every candidate against the NCBI BLAST database to rule out off-target matches to related viruses, host plant genetic material, or other organisms associated with sugarcane production. The reverse complements of the selected sites were appended to the LwaCas13a direct repeat sequence to generate functional guide RNAs, which were then synthesized commercially.

Because working with quarantine pathogens requires specialized containment, the team first validated the assay using synthetic pseudo-virus targets. They embedded the five 28-nucleotide target sequences for each virus into 700-base-pair synthetic DNA constructs separated by scrambled sequences, placed under a T7 promoter, and produced single-stranded RNA by in vitro transcription. Serial log dilutions of these RNA targets established the limit of detection, which varied among target sites but reached approximately 1.5 picomolar at its best. The top-performing guides were site 5 on ScMV, site 3 on ScSMV, and site 1 on ScYLV. The authors note that this sensitivity represents roughly a tenfold improvement over a recent report of amplification-free Cas13 detection of plant viruses, although they caution that the intrinsic enzyme kinetics of Cas13 still limit how low the detection floor can go without pre-amplification.

A key feature of the platform is its multiplexing capacity. In a cross-reactivity matrix, the researchers combined every pseudo-virus target with every crRNA and found that fluorescence rose only when a viral target matched its corresponding guide, with matched wells producing relative fluorescence units between roughly 39,000 and 60,000 compared with 4,500 to 8,100 for mismatched combinations. Strikingly, after just 15 to 20 minutes the fluorescent signal was strong enough to be visible with a standard gel documentation reader, an instrument not designed for such measurements. This strict specificity means a single microplate can screen a sample for any of the three viruses in one multiplexed well while simultaneously running simplex wells for each virus individually, yielding both detection and genotyping in one run.

The decisive test came with real plant material. Working inside the USDA-APHIS quarantine facility, the team extracted bulk RNA from infected sugarcane and sorghum plants—sorghum serving as an alternative host for ScMV—using the same commercial kit employed by the agency’s own diagnosticians. They first benchmarked the samples with five conventional RT-PCR protocols, including genus-level potyvirus assays and two separate primer sets for ScYLV that exist because of that virus’s considerable genetic diversity. The CRISPR assay then processed the same extracts directly, with no dilution and no cDNA synthesis step, reading fluorescence over a two-hour run at 37 degrees Celsius.

The two methods broadly agreed, but the discrepancies proved illuminating. A sorghum sample called Rio tested positive in the generic Potyvirus RT-PCR protocols, but only the CRISPR assay—and a follow-up sequencing step—could pin the infection specifically on ScMV, since the conventional protocols detect the genus rather than the species. Another sorghum sample, Z1536, produced signals above threshold for all three viruses in the CRISPR assay while remaining negative or ambiguous by RT-PCR, and sugarcane sample Z1502, which showed no RT-PCR bands at all, yielded a clear CRISPR positive for ScYLV. The authors attribute such gaps to several factors: low or seasonally fluctuating viral titers, mutations at primer binding sites that can silence PCR amplification, the added variability of the two-step cDNA-plus-amplification workflow, and possible weak cross-reactivity of the Poty2 primer set with ScSMV observed in sample Z1501.

Beyond speed, the platform offers practical advantages for diagnostic laboratories. The conventional workflow requires five separate RT-PCR protocols, each with cDNA preparation and post-amplification gel electrophoresis, and a skilled technician might need a day or two to fully characterize even one sample. The CRISPR assay completes detection and virus identification in four hours or less for high-titer infections, on a single plate, with fewer handling steps and correspondingly fewer opportunities for contamination. The fluorescence-based readout also provides a semi-quantitative measure of viral load, whereas conventional RT-PCR as performed here is essentially a presence-or-absence test. To guard against false positives from natural degradation of the RNA reporter during the long incubation, the team set a conservative threshold of three standard deviations above the mean of background-subtracted negative control values.

The researchers are candid about the method’s limits. At roughly 1.5 picomolar, the sensitivity may not suffice for very early or light infections, where RT-PCR or an added pre-amplification step would still be needed, and the study was constrained by a limited number of infected samples, leaving more rigorous statistical benchmarking on larger field collections as the obvious next step. Still, because the assay needs only a single conserved target region per virus—rather than the paired primer sites PCR demands—and Cas13 requires no PAM, redesigning guides as viruses evolve is straightforward. The team envisions extending the approach with kinetic barcoding for richer multiplexing, engineered guides for greater specificity, and enhanced collateral cleavage activity, ultimately expanding the panel to many more pathogens and molecular markers.

For an industry in which viruses can account for more than half of yield reduction and global commerce in planting material keeps introducing quarantine pathogens to new regions, a rapid, amplification-free test that names its target within hours could materially change surveillance practice. The authors suggest that, equipped with cold storage and a suitable plate reader, the workflow could even be adapted into field-deployable diagnostics, offering a way to catch outbreaks early enough to contain them before the damage reaches the mill—or the next season’s seed cane.

Subject of Research: Amplification-free CRISPR-Cas13 detection of quarantine-significant sugarcane RNA viruses

Article Title: CRISPR-Cas13-based amplification-free detection of three quarantine-significant sugarcane viruses

Article References: Lagner, J., Paulson, A., Schulden, T., Adhikari, B., Koob, J., Vakulskas, C., & Qi, Y. (2026). CRISPR-Cas13-based amplification-free detection of three quarantine-significant sugarcane viruses. Plant Cell Reports, 45(10), Article 307. https://doi.org/10.1007/s00299-026-03994-4

Image Credits: AI Generated

DOI: 10.1007/s00299-026-03994-4

Keywords: CRISPR-Cas13, LwaCas13a, sugarcane viruses, Sugarcane mosaic virus, Sugarcane streak mosaic virus, Sugarcane yellow leaf virus, plant pathology, molecular diagnostics, amplification-free detection, multiplexed assay, RNA viruses, agricultural biotechnology

The central logic of the host-targeting approach rests on a fundamental constraint of virology. Viruses are genomic minimalists. They carry only a handful of their own proteins and rely extensively on host-cell factors for nearly every step of replication, from translation of viral messages to genome replication, packaging, and assembly. RNA viruses in particular, which include many of the most medically important pathogens such as influenza, SARS-CoV-2, Ebola, dengue, and enteroviruses, depend heavily on the host cell’s RNA-processing infrastructure. Host RNA-binding proteins, which normally regulate messenger RNA splicing, stability, localization, and translation, are among the most frequently co-opted factors. When a virus enters a cell, these proteins are recruited to viral RNA genomes and transcripts, where they perform functions essential to the invader.

This dependence creates what antiviral researchers call a genetic vulnerability. Because the virus cannot easily replace a missing host function with one of its own, a drug that blocks a critical host RNA-binding protein interaction can place the virus in an evolutionary bind. Resistance mutations that arise against direct-acting antivirals, which typically alter the viral target protein so the drug no longer binds, are far harder to evolve against host targets. The host protein remains unchanged, and any viral mutation that restores dependence on the blocked pathway would itself carry a fitness cost. The result, according to the review, is a higher barrier to drug resistance, one of the persistent weaknesses of conventional antiviral development.

The broad-spectrum potential of this strategy is equally significant. Traditional antivirals are narrow: a drug designed to inhibit the influenza neuraminidase does nothing against coronaviruses, and a protease inhibitor for hepatitis C has no effect on Ebola. This narrowness has repeatedly left clinicians without options when new pathogens emerge, as the early months of the COVID-19 pandemic made painfully clear. Host-targeted antivirals, by contrast, could in principle cover many viruses at once. If diverse RNA viruses all require, for example, host proteins involved in RNA cap formation, translation initiation, or RNA granule dynamics, then a single molecule that modulates that shared host pathway could suppress multiple unrelated infections. Such agents could be stockpiled in advance of outbreaks and deployed rapidly against known and unknown threats, a concept increasingly discussed under the umbrella of pandemic preparedness.

The technical challenge, the article acknowledges, is selectivity. Human RNA-binding proteins are not optional accessories; they are central to the biology of every cell. An inhibitor that shut down a host RNA-binding protein globally would be toxic. The most promising targets, therefore, are those for which viral dependence is unusually high or for which the host can tolerate partial inhibition. Some RNA-binding proteins, such as certain members of the heterogeneous nuclear ribonucleoprotein family and the La autoantigen, have known viral interaction surfaces that are structurally distinct from the regions used for normal cellular functions. Drugs that bind to these viral-specific interfaces, or that disrupt the protein-protein contacts between host factors and viral polymerases or nucleocapsids, could in theory block the virus while sparing the host pathway. Structure-based drug design, enabled by high-resolution cryo-electron microscopy and computational modeling, is making such precision interference increasingly feasible.

Recent advances in the RNA biology toolkit have accelerated the identification of candidate targets. Enhanced crosslinking and immunoprecipitation methods now allow researchers to map, at single-nucleotide resolution, which host proteins bind which viral RNAs inside infected cells. Proteomics approaches quantify how the composition of RNA-bound protein complexes shifts during infection. Together, these techniques have generated dense interaction maps that reveal which host RNA-binding contacts are recurrent across viral families and therefore represent the most broadly useful drug targets. The review synthesizes this growing literature to highlight proteins whose perturbation has been shown, in cell culture and in some cases animal models, to impair multiple viruses simultaneously while remaining tolerable to the host cell.

Several concrete examples illustrate the concept’s maturity. Host proteins involved in mRNA capping and methylation are recruited by viruses ranging from coronaviruses to flaviviruses, which either steal or mimic cap structures to ensure their RNAs are translated. Interfering with these host cofactors can block a step the virus cannot perform independently. Similarly, stress granule components and other RNA granule proteins have emerged as double-edged factors: viruses must either suppress or exploit granule formation, and pharmacological modulation of granule dynamics has been shown in multiple studies to restrict infection. RNA-binding proteins that regulate innate immune sensing, such as those controlling the accessibility of viral RNA to pattern-recognition receptors, offer another angle, since modulating them can amplify the cell’s own antiviral response rather than directly inhibiting the virus.

Translation of these findings into approved medicines remains a work in progress, and the review is candid about the obstacles. Host-targeted drugs must clear a higher toxicity bar than direct-acting antivirals, because their targets are present in healthy tissue. Delivery, dose scheduling, and patient selection all require careful optimization. Combination regimens, pairing a host-targeted agent with a traditional direct-acting antiviral, may offer the best of both worlds: the broad coverage and high resistance barrier of host targeting combined with the potency and safety profile of virus-specific inhibition. Such combinations could also be effective against chronic infections, where resistance development during long-term therapy is a persistent clinical problem. The authors point to the success of host-targeted drugs in other fields, including certain oncology therapies, as evidence that drugging host factors is a realistic goal when the biology is well understood.

The strategic case for investing in this area is framed against the backdrop of recurring epidemic threats. RNA viruses continue to spill over from animal reservoirs, and the review argues that a portfolio of broad-spectrum host-targeted antivirals would function as a form of pharmaceutical insurance, providing immediately deployable countermeasures during the critical window before pathogen-specific drugs and vaccines can be developed. The COVID-19 pandemic demonstrated both the speed with which a novel virus can circle the globe and the difficulty of repurposing narrow antivirals against it. Building a validated pipeline of host RNA-binding protein targets, supported by structural biology, chemical biology, and rigorous animal models, is presented as a research priority that could materially change the outcome of the next outbreak.

Subject of Research: Host RNA-binding proteins as broad-spectrum antiviral drug targets

Article Title: Host RNA-binding proteins as broad-spectrum targets for antiviral therapy

Article References: Biswas, S. (2026). Host RNA-binding proteins as broad-spectrum targets for antiviral therapy. npj Viruses. https://doi.org/10.1038/s44298-026-00234-0

Image Credits: AI Generated

DOI: 10.1038/s44298-026-00234-0

Keywords: antiviral therapy, RNA-binding proteins, host-directed antivirals, RNA viruses, broad-spectrum antivirals, drug resistance, virus-host interactions, pandemic preparedness, viral replication, innate immunity, SARS-CoV-2, influenza